STERIS has earned a perfect Piotroski F-Score of 9/9 and analysts carry a consensus target implying 25% upside, but the stock is in a confirmed downtrend with both price and volume distribution pointing lower, and an elevated put-to-call ratio of 4.62 reflects significant bearish positioning by options market participants.
Thesis pillars
- Piotroski Perfect Quality Score→Stable
- Analyst Consensus 25pct Upside↓Deteriorating
- Elevated Put Call Bearish Positioning→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed May 29, 2026· older than 90 days
STERIS plc (Ireland) (STE) Stock Analysis
Momentum Cont setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $231.35, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60; Analyst target reached - limited upside remaining.
STERIS sells sterilization and infection prevention products and services globally through Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments, serving hospitals, medical device manufacturers, and pharmaceutical companies. Revenue comes from... Read more
Hold if already holding. Not a fresh buy at $231.35, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60; Analyst target reached - limited upside remaining. Chart setup: Trend continuation, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Score 5.3/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
About STERIS plc (Ireland)
About STERIS plc (Ireland)
STERIS held $490.7 million in capital equipment backlog at March 31, 2026 — split between $392.1 million in Healthcare and $98.7 million in Life Sciences — reflecting demand for sterilizers, surgical tables, washers, and related equipment globally. The company divested its Dental segment as discontinued operations in fiscal 2025, leaving three reporting segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Ireland-domiciled and listed on the NYSE, STERIS operates contract sterilization and laboratory testing facilities across the Americas, Europe, and Asia, with 606 U.S. patents and 2,402 patents in other jurisdictions held at March 31, 2026.
STERIS earns revenue through consumable sales (cleaning chemistries, sterility assurance products, endoscopy accessories), capital equipment sales, and service contracts spanning installation, preventive maintenance, instrument repair, and outsourced reprocessing. The Healthcare segment addresses hospital sterile processing departments and procedural centers, with competitors including Getinge, Stryker, Olympus, and Belimed. The AST segment provides contract sterilization and laboratory testing to medical device and pharmaceutical manufacturers through a global facility network; EO (ethylene oxide) and cobalt-60 radioisotope are the two primary sterilization inputs the 10-K identifies as single-sourced in certain regions. The Life Sciences segment focuses on aseptic pharmaceutical manufacturing support, including vaporized hydrogen peroxide decontamination systems and high-purity water generators. In each of the three segments, no customer represented more than 10% of segment revenues in fiscal 2026.
Show full overview
The 10-K explicitly names ethylene oxide and cobalt-60 as materials single-sourced in certain regions, both essential to AST contract sterilization operations. To address cobalt-60 supply risk, STERIS has been expanding irradiation capacity using accelerator-based technologies. If regional single-source supply of EO or cobalt-60 is disrupted, AST could face capacity constraints that may impact medical device manufacturers relying on contract sterilization turnaround. STERIS's Ireland domicile also exposes the company to GloBE Pillar Two minimum tax rules adopted across EU and other jurisdictions, which the 10-K notes could subject the company to additional income taxes in jurisdictions where the effective rate falls below 15%.
See also: Healthcare · Medical Devices
From STERIS plc (Ireland)'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 31, 2026Recent Developments — STERIS plc (Ireland)
Latest news
- NEWS Will Upcoming Results Change STERIS (STE) Stock Narrative - Simply Wall St — Simply Wall St Oct 31, 2026 neutral
- NEWS STERIS (STE) Dividend Reaffirms The Story As Undervalued Views Face A P E Reality - Yahoo Finance — Yahoo Finance Oct 31, 2026 positive
- NEWS STE Q2'26 Earnings: revenue estimate is 1.56B USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS STERIS declares $0.69 quarterly dividend payable in December By Investing.com - Investing.com Nigeria — Investing.com Nigeria Oct 28, 2026 positive
- NEWS STE Stock Price Today - CoinDesk — CoinDesk Sep 27, 2026 neutral
Latest item Oct 31, 2026 · Generated 2026-11-04T11:59:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierethylene oxide and cobalt-6010-K Item 1: 'single-sourced in certain regions of the world, such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations'
Material Events(8-K, last 90d)
- 2026-05-07Item 5.02LOWDirector Richard C. Breeden (18 years of service) will not stand for reelection at the 2026 AGM; no disagreement cited. Pierre Boulud (CEO of bioMerieux) appointed to the Board on May 5, 2026, expanding Board from nine to ten members.SEC filing →
- 2026-04-06Item 5.02LOWAmendment to Aug 5, 2025 Transition Agreement with former CFO Michael J. Tokich: part-time senior financial advisor role extended through March 31, 2027 at reduced annual salary of $60,000. Routine compensatory arrangement for former officer.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $231.35, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60; Analyst target reached - limited upside remaining. Chart setup: Trend continuation, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Analyst target $226.82 reached (−2.0%), stop $219.89 (−5.2%), A.R:R -0.2:1. Score 5.3/10, moderate confidence.
Analyst target $226.82 reached (−2.0% from $231.35); no take-profit level is published. Analyst target $226.82 reached (−2.0%), stop $219.89 (−5.2%), A.R:R -0.2:1. Stop-loss: $219.89.
Concentration risk — Supplier: ethylene oxide and cobalt-60; Analyst target reached - limited upside remaining.
STERIS plc (Ireland) trades at a P/E of 28.3 (forward 18.8). TrendMatrix value score: 5.2/10. Verdict: Hold.
13 analysts rate STE, with a consensus score of 3.9/5. 7 analysts publish price targets averaging $261.
What does STERIS plc (Ireland) do?STERIS sells sterilization and infection prevention products and services globally through Healthcare, Applied...
STERIS sells sterilization and infection prevention products and services globally through Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments, serving hospitals, medical device manufacturers, and pharmaceutical companies. Revenue comes from consumables, capital equipment (sterilizers, surgical tables), and service contracts; the AST segment operates a global contract sterilization network on an outsourced basis.